ERBB2 and breast cancer: In this literature review, we describe the epidemiology of patients with HER2+ metastatic or advanced BC with BM, including prognostic factors for developing BM, factors predictive of survival among patients with BM, and differences in survival and time to progression by HER2-targeting drug class based on drug mechanism of action.